According to Edelweiss Research note the three observations made US FDA on Miryalaguda plant relates to deviations on deficiency of test methods, procedures describing the calibration of instruments and certain recording keeping practices. Money Control, 2 weeks ago
Dr Reddy's receives 3 USFDA observations for Miryalaguda plant - Money Control, 1 month ago
Can sort out USFDA concerns on Telangana plant: Dr Reddy's - Money Control, 4 weeks ago
2 images for "miryalaguda"
Drug firm Dr Reddy's Laboratories today said the US health regulator has made three observations after completing inspection of its Miryalaguda facility.DNA, 1 month ago USFDA concludes inspection of Dr Reddy's Miryalaguda facility Money Today, 1 month ago How Dr Reddy's plans to win the US market Rediff.com, 1 week ago Plants of Pharma major, Dr. Reddy's to be re-audited by USFDA India Infoline, 2 months ago
, an integrated global pharmaceutical company, announced that the audit of the company's API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017. The company have been issued a Form 483 with three observations, which the ...Myiris, 1 month ago
Posted by Equitymaster Most of the global financial markets ended the week on a flat note. The Brazilian index registered a 3.3% drop over the week, making it the top loser. Most of the global indices ended the week on a flattish note as they awaited cues ...Equitymaster.com, 2 weeks ago
Posted by Equitymaster Asian equity markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.15%, while the Hang Seng is down 0.99%. The Shanghai Composite is trading down by 0.86%. Stock markets in the US finished their previous ...Equitymaster.com, 3 weeks ago
Posted by Equitymaster After opening the day in the green, the Indian share markets have continued to trade strong and are currently trading above the dotted line. With the exception of stocks in the FMCG sector all sectoral indices are trading on a positive ...Equitymaster.com, 2 months ago
Suit alleges fraud by hiding significant deficiencies in CGMP regulations enforced by US health regulator. Seoul-based biotech company Mezzion Pharma has filed a suit against Dr Reddy’s Laboratories in a US court. It has alleged the Hyderabad-based supplier had committed fraud by hiding significant deficiencies in the Current Good Manufacturing Practice, or CGMP, regulations enforced by the US health regulator. In the suit, filed in the state of New Jersey, Mezzion seeks to “recover ...Rediff.com, 2 months ago
on your WebpageAdd Widget >Get your members hooked!